Navigation Links
ABAXIS Realigns North American Medical Sales and Marketing
Date:4/7/2009

UNION CITY, Calif., April 7 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced a reorganization of its North American sales and marketing organization resulting from a strategic review of the company's medical business. As a part of this reorganization, Christopher M. Bernard, Vice President of North American Medical Sales and Marketing, has ceased to be an employee of the company.

Abaxis' Medical Area Sales Directors, Mike Petrunich and Matt Rapp, will continue to be responsible for managing and growing the field sales teams. Rick Betts, Director of Medical Marketing, will coordinate their efforts with the in-house marketing team and all will report to Clint Severson, chief executive officer, until a successor to Mr. Bernard is named. The Company has hired and retained a recruiting firm to find a successor; eligible candidates could come from inside or outside the company.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Safe Harbor

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the company's ability to recruit and retain sales and marketing personnel, the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, general market conditions, competition and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Contact:   Clint Severson             Lytham Partners, LLC
               Chief Executive Officer    Joe Dorame, Robert Blum and Joe Diaz
               Abaxis, Inc.               602-889-9700
               510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abaxis, Inc. to Attend Lazard Capital Markets Medical Technologies Conference
2. Abaxis, Inc. to Present at Sidoti & Companys Thirteenth Annual New York Emerging Growth Institutional Investor Forum
3. Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009
4. ABAXIS Announces Launch of Two New Products at the NAVC
5. ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
6. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
7. Abaxis, Inc. to Present at Needham & Companys Eleventh Annual Growth Stock Conference
8. Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status
9. Abaxis, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
10. Abaxis to Report Second Quarter Fiscal 2009 Financial Results Monday, October 27, 2008
11. Abaxis, Inc. to Present at CL Kings Sixth Annual Best Ideas Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... With less ... from acne, access to quality care can be limited while the desire to conquer ... offers customized prescription acne care for every customer online, today released its inaugural survey ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Columbus OH. Dr. ... as one of few medical professionals in the country to sit on the 2017 ... Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work ... a variety of business channels. , While many results are clear, much of PR ... program. , When it comes to measurement, firms should always take an all-inclusive ...
(Date:3/28/2017)... ... ... skin is a common and unwelcomed occurrence in people of all ages, genders and ethnicities. ... the discussion of dealing with excess skin oil. “Oily skin is a challenge to many ... help remove the oily shine while keeping the skin fresh and clean,” says Dr. Au. ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
(Date:3/27/2017)... Summary This report provides all the information ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
Breaking Medicine Technology: